A phase 1 study with LOXO-101 in soft tissue sarcoma with LMNA–NTRK1 fusion and non-small cell lung cancer harboring TPR-NTRK1 fusion showed a good response [35, 36]. This evidence concerns the gene NTRK1 and soft tissue sarcoma.